The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the study is to evaluate the long‑term safety and tolerability of the medication. Over several months, participants will take the drug each day and attend regular clinic visits where doctors will check blood work (laboratory tests that look at how the body is functioning), perform an ECG (a quick test that records the heart’s electrical activity), measure vital signs such as blood pressure and weight, and conduct simple memory and thinking assessments to see how cognition changes.

Throughout the trial, any side effects or new health problems will be recorded, and participants may stop the medication if serious issues arise. The overall goal is to determine whether the drug can be used safely for people living with this condition.

The study is a follow-up, or extension, of earlier research and is designed to continue for a long period. During the study, participants will take the study tablets and return for regular checkups so the study team can watch for any health problems and see how the treatment is being tolerated over time. The study compares the two remibrutinib doses with placebo in a blinded way, which means the treatment given is not revealed to the participants or the study team during the study.

People in the study will receive either VMX-C001 or the usual care used for this situation. Some participants may also receive heparin, another blood-thinning medicine, if planned by the treating team. The study is designed to compare the two approaches during the procedure and shortly afterward, without changing the urgent care needed for the surgery or procedure.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The purpose of this research is to determine how well ruxolitinib cream works in treating moderate atopic dermatitis in young patients. During the study, participants will apply either ruxolitinib cream or the vehicle cream to affected areas of their skin, excluding the scalp. The treatment period lasts for 8 weeks, followed by an extended observation period.

The study will monitor changes in skin condition, including improvements in rash coverage, intensity of itching, and overall disease severity. Blood samples will be collected from some participants to measure how much of the medication enters the bloodstream. The research will also track any side effects that may occur during the treatment period.

The purpose of this research is to evaluate how well different doses of Rocatinlimab work compared to placebo in reducing itching in people with Prurigo Nodularis. The medication will be given as a subcutaneous injection (an injection under the skin). The study will last for 52 weeks, during which participants will receive either Rocatinlimab or placebo.

Throughout the study, participants will need to keep a daily record of their symptoms, including itching intensity and skin pain. Doctors will regularly examine the skin nodules and monitor how the treatment affects participants’ quality of life and sleep. The study will also track any side effects that may occur during the treatment period.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to see how effective and safe these treatments are for patients with this type of lung cancer. Participants will receive either rilvegostomig or pembrolizumab, along with chemotherapy drugs such as carboplatin and paclitaxel. The study will monitor how long patients live and how long they remain free from cancer progression, which means the cancer does not get worse. The study will also look at other factors like the overall response to the treatment and any side effects experienced.

Participants will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out which combination of treatments works best for this type of lung cancer.

The study follows people for a long period and looks at whether normal thyroid function can be kept after treatment has been stopped. During the study, adults receive the study medicine and are then observed over time to see whether thyroid levels remain stable without ATD (anti-thyroid drugs, medicines that lower thyroid hormone). Some participants may stop the study medicine earlier or later than others as part of the study plan. The study also checks whether TRAb (thyroid-stimulating hormone receptor antibodies, proteins made by the immune system that can affect the thyroid) are no longer found in the blood.

The study is designed as a long-term extension, meaning it continues to follow people who have already taken part in earlier research with this medicine. Information is collected over many months, with the main follow-up lasting up to 52 weeks after treatment changes. The study uses groups of participants to compare how long thyroid control lasts after stopping treatment and how often the disease returns, also called a relapse.

The study will compare FWY003 with placebo in people with this eye condition. It is a randomized study, which means the treatment is assigned by chance, and double masked, which means neither the participants nor the study team know who receives FWY003 or placebo during the study. Over time, the study follows changes in the damaged area in the eye and also watches for side effects and other health changes. The study lasts for many months and includes regular visits during which eye health and general well-being are reviewed.

Adults who have had a kidney transplant are assigned to one of the study treatments. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known to the doctors and the participants. Frexalimab is given as an injection, while tacrolimus is taken by mouth as a capsule. The study follows participants for several years after transplantation to observe how the kidney is doing and to watch for signs of rejection, graft loss, death, and side effects.

During the study, regular checkups are done to monitor kidney function, general health, and possible unwanted effects of treatment. The study also looks at new health problems that can happen after a transplant, such as high blood pressure, abnormal blood fats, and diabetes. eGFR is one of the kidney tests used in the study; it is an estimate of how well the kidney is filtering the blood.

The study is planned to last about 50 weeks for each person. During the study, treatment is given at regular times, and health checks are done over the course of the trial to watch for side effects and other changes in health. The study also looks at lung function, which means how well the lungs move air in and out.

The study will include adults between 40 and 80 years old who have moderate to severe lung disease with frequent flare-ups, meaning they have had at least two moderate flare-ups or one severe flare-up in the past year. Participants need to have higher levels of certain white blood cells called eosinophils in their blood. They should already be using three types of inhaled medications for their lung condition, including an inhaled steroid, for at least six months before joining the study. The study will look at how often flare-ups happen during treatment and will measure this over time.

During the study, participants will receive injections of either the study medication or placebo for up to 104 weeks. The study will measure how many flare-ups occur, how long it takes until the first flare-up happens, and how the disease affects daily life and breathing symptoms. Doctors will also track how many flare-ups require emergency room visits or hospital stays. Throughout the study, participants will continue taking their regular inhaled medications as prescribed by their doctor.

The purpose of this study is to see how effective Plozasiran is at reducing triglyceride levels in people with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo and will be monitored over a period of 12 months. During this time, the study will measure changes in triglyceride levels and monitor for any side effects. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo.

Participants will receive regular injections and attend scheduled visits to track their progress. The study aims to provide valuable information on the safety and effectiveness of Plozasiran, which could lead to new treatment options for people with severe hypertriglyceridemia. This research is important for understanding how to better manage this condition and improve patient outcomes.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

Participants in the study will receive Batoclimab through a subcutaneous injection, which means it is injected under the skin. The treatment will be administered once a week for a total of 24 weeks. For the first 12 weeks, participants will receive a dose of 680 mg, followed by a reduced dose of 340 mg for the remaining 12 weeks. Some participants will receive a placebo, which looks like the treatment but does not contain the active substance.

The study aims to observe changes in the condition of the eyes, specifically looking at the reduction in eye protrusion, known as proptosis, by the end of the 24-week period. The trial will also monitor other aspects of the disease, such as changes in eye inflammation and overall eye health. The goal is to determine if Batoclimab can effectively improve symptoms of TED compared to the placebo.

The study is divided into two stages. In the first stage, researchers will determine the best dosing schedule for the eye drops. In the second stage, they will compare the effects of the eye drops to a placebo over a period of 52 weeks. Participants will be randomly assigned to receive either the OCS-01 eye drops or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a “double-masked” study, which helps ensure that the results are unbiased.

Throughout the study, participants will have regular check-ups to monitor their eye health and vision. The main focus will be on changes in vision clarity, measured by a test called Best Corrected Visual Acuity (BCVA). This test helps determine how well a person can see with the best possible glasses or contact lenses. The study aims to see if the OCS-01 eye drops can improve vision in people with DME compared to those who receive a placebo. Participants will also be monitored for any side effects or safety concerns related to the treatment.

Participants in the study will receive either eneboparatide or a placebo for a period of 24 weeks. The treatment is administered through a pre-filled pen for subcutaneous injection, which means it is injected under the skin. The goal is to evaluate how effective eneboparatide is in reducing the need for active vitamin D and oral calcium supplements, and in maintaining normal serum calcium levels. The study will also assess changes in symptoms and physical functioning of the participants.

In addition to eneboparatide, the study involves other medications such as calcitriol and calcium carbonate, which are commonly used to manage calcium levels. Another medication, alfacalcidol, is also part of the study. These medications are used to help understand the overall effectiveness of the new treatment. The study aims to provide valuable information on the safety and benefits of eneboparatide for people living with chronic hypoparathyroidism.

The purpose of this study is to determine if deucravacitinib is more effective than a placebo in treating people with active SLE. Participants in the study will be randomly assigned to receive either deucravacitinib or a placebo. The study will last for a period of 52 weeks, during which participants will be monitored for their response to the treatment. The main goal is to see how many participants achieve a significant improvement in their SLE symptoms by the end of the study period.

Throughout the study, participants will be assessed for changes in their condition, including improvements in joint pain, skin rashes, and overall disease activity. The study will also track any side effects or adverse events that may occur. By the end of the study, researchers hope to gather valuable information on the potential benefits and risks of using deucravacitinib for treating SLE, which could lead to better treatment options for those affected by this condition.

Participants will be assigned to receive either clemizole hydrochloride in the form of an oral solution or a placebo. The study is designed as a double-blind trial, meaning that neither the participants nor the researchers will know which substance is being administered during the process. The course of the study involves different stages, including a period where the dose is gradually adjusted, followed by a maintenance period where the treatment is continued.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The purpose of this study is to find out if CagriSema can improve markers that show how chronic kidney disease is progressing in people with type 2 diabetes who are living with overweight or obesity. Participants may also be taking other medicines during the study, such as enalapril maleate, dapagliflozin propanediol, or finerenone, which are used to help protect the kidneys and manage related conditions. The study will measure changes in urine protein levels, kidney function, body weight, waist size, blood sugar control, and blood pressure. It will also track any side effects or health problems that occur during treatment.

During the study, participants will receive their assigned treatment for up to 35 weeks. They will attend regular visits where measurements will be taken and blood and urine samples will be collected to check how well the treatment is working and to monitor safety. The study team will look at changes from the start of the study to the end of treatment to understand the effects of each treatment option.

People taking part in the study will be randomly assigned to receive either one injection of the experimental treatment or regular injections of the approved medication. Before starting the main part of the study, participants will receive one injection of the approved medication to make sure their condition responds to this type of treatment. During the study, doctors will measure vision using an eye chart and will take images of the eye to see how the condition is changing. The main measurement will be the change in vision after one year of treatment. Doctors will also track how many additional injections are needed and whether the experimental treatment can reduce the need for repeated injections compared to the standard treatment.

The study will last several years and will continue to follow participants to see how long the effects of the treatments last. Throughout the study, participants will have regular visits where their vision will be tested and their eyes will be examined. The study aims to determine whether the single injection of gene therapy can provide lasting benefits and reduce the treatment burden for people with this eye condition.

The purpose of the study is to learn how empagliflozin works in the bodies of children and teenagers with chronic kidney disease, to see if it is safe for them, and to find out if it helps their kidney disease. The study will measure how much of the medicine gets into the blood, check for any unwanted effects, and see if the medicine helps improve kidney function. The study will look at changes in protein levels in the urine, which is one way to measure how well the kidneys are working, and changes in how well the kidneys filter waste from the blood.

The study has two parts. In the first part, participants will be randomly assigned to receive either empagliflozin or placebo for 24 weeks, and neither the participants nor the doctors will know which treatment they are receiving. After this period, there will be an open-label extension where all participants will know they are receiving empagliflozin. The total treatment period can last up to 72 weeks. During the study, participants will continue taking their regular medicines for kidney disease, which may include medicines that help protect the kidneys. Regular check-ups will be done to monitor the participants’ health and kidney function throughout the study.

This is an extension study, which means it is designed for people who have already completed another study with the same medication. Participants will take SPT-300 for six weeks, and everyone in the study will receive the active medication rather than a placebo. The study is described as open-label, which means both the participants and the doctors will know what treatment is being given. During the study, participants will have regular visits where doctors will check for any unwanted effects, measure vital signs like blood pressure and heart rate, and perform blood tests and physical examinations. The doctors will also use questionnaires to assess mood, anxiety levels, and how the condition affects daily life.

Throughout the six weeks, the medical team will carefully monitor participants for any side effects or health changes. Special attention will be given to thoughts of self-harm using a specific rating scale designed for this purpose. The study will also look at whether symptoms of depression and anxiety improve over time. Participants will need to avoid alcohol and recreational drugs during the study and must use effective birth control methods if they are able to have children. The maximum daily dose of the medication is 375 milligrams, and treatment will continue for the full six-week period.

During the study, participants will be randomly assigned to receive either ML-007C-MA or placebo for a treatment period of seven weeks. The maximum daily dose of ML-007C-MA that may be given is 210 milligrams. Participants will need to have a care partner who can provide information about their symptoms and help them follow the study requirements. The care partner must be in regular contact with the participant and will need to attend all study visits with them. Participants must have been living in the same home or care facility for at least six weeks before joining the study and are expected to stay there throughout the study period.

Throughout the study, doctors will measure changes in hallucinations and delusions using rating scales that assess the severity of these symptoms. They will compare scores from the beginning of the study to scores after seven weeks of treatment. The study will also look at whether the treatment helps with other symptoms such as agitation and aggression in some participants, and will measure how much distress caregivers experience related to the participant’s hallucinations and delusions. Participants must be between 55 and 90 years old and meet specific criteria related to their Alzheimer’s disease diagnosis and the presence of psychotic symptoms for at least two months. A brain scan using MRI or CT must be available or completed during the screening period.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The study aims to determine whether the combination of divarasib and pembrolizumab works better than the standard treatment combination in treating this type of lung cancer. The medications will be given through different routes – divarasib as tablets taken by mouth, while pembrolizumab, pemetrexed, carboplatin, and cisplatin are given through an intravenous infusion (through a vein).

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. They will also assess how the treatment affects patients’ quality of life and symptoms related to their cancer, such as cough and breathing difficulties. The study will measure how long patients live without their cancer getting worse and their overall survival time.

The purpose of this study is to determine if ALXN2420 can help lower levels of a hormone called IGF-1 in people with acromegaly when combined with standard treatments. The study compares ALXN2420 to placebo, with both being given alongside regular acromegaly medications. The treatment period lasts for 15 weeks, during which participants receive either ALXN2420 or placebo through injections under the skin.

Throughout the study, participants continue their regular acromegaly medications, which are given as injections either into the muscle or under the skin once every four weeks. The study monitors how well the combination of treatments works by measuring hormone levels and tracking any changes in symptoms. Participants also complete questionnaires about their quality of life and overall health during the study period.

The study involves patients who have moderate to severe COPD and show specific signs of inflammation in their blood. During the study, participants receive either dupilumab (also known as SAR231893) or a matching placebo as injections under the skin for 24 weeks. The medication is provided in pre-filled syringes, and participants continue taking their regular COPD medications throughout the study.

The research uses special lung imaging techniques to examine how the treatment affects mucus in the airways. High-resolution Computed Tomography (HRCT) scans are used to look at changes in the lungs over the course of treatment. The study also monitors the safety of the treatment and any changes in breathing ability.